home / stock / stml / stml news

STML News and Press, Stemline Therapeutics Inc. From 07/08/19

Stock Information
Company Name: Stemline Therapeutics Inc.
Stock Symbol: STML
Market: NASDAQ
Website: stemline.com
Menu
STML STML Quote STML Short STML News STML Articles STML Message Board
Get STML Alerts

News, Short Squeeze, Breakout and More Instantly...
STML - Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, following its annual shareholder meeting, highlights recent clinical and regu...
STML - Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

NEW YORK, June 17, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics announced today that ELZONRIS (tagraxofusp) was the subject of preclinical dat...

STML - Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that ELZONRIS™ (tagraxofusp) is the subject of three clinica...

STML - Stemline Therapeutics: Updating The Investment Thesis

It is a principle of diplomacy that one must know something of the truth in order to lie convincingly ." - Tom Clancy, The Hunt for Red October Today, we revisit a small oncology name. Like most small biotech stocks (and the majority of the overall market), the shares have been under pres...
STML - Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced that ELZONRIS™ (tagraxofusp) Phase 2 clinical data in chroni...

STML - Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress

NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in blastic plasmacyt...

STML - Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting

NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp) clinical data in chronic myelomono...
STML - Stemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript

Stemline Therapeutics, Inc (STML) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Ken Hoberman – Chief Operating Officer Ivan Bergstein – Chief Executive Officer Robert Francomano – Senior Vice President Global Head of Commercial...

STML - Stemline Therapeutics misses by $0.07, beats on revenue

Stemline Therapeutics (NASDAQ: STML ): Q1 GAAP EPS of -$0.73 misses by $0.07 . More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

STML - Stemline Therapeutics Reports First Quarter 2019 Financial Results

Net revenue for ELZONRIS was $5.05 million for the first quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the de...
Previous 10 Next 10